Yamamoto S - Search Results

1

Fibroblast Growth Factor 23 and Mortality Among Prevalent Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study.

Komaba H, Fuller DS, Taniguchi M, Yamamoto S, Nomura T, Zhao J, Bieber BA, Robinson BM, Pisoni RL, Fukagawa M. Komaba H, et al. Among authors: yamamoto s. Kidney Int Rep. 2020 Aug 20;5(11):1956-1964. doi: 10.1016/j.ekir.2020.08.013. eCollection 2020 Nov. Kidney Int Rep. 2020. PMID: 33163716 Free PMC article.

2

Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.

Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fukagawa M. Kazama JJ, et al. Among authors: yamamoto s. Kidney Int. 2005 Mar;67(3):1120-5. doi: 10.1111/j.1523-1755.2005.00178.x. Kidney Int. 2005. PMID: 15698453 Free article.

3

Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism.

Kazama JJ, Omori K, Yamamoto S, Ito Y, Maruyama H, Narita I, Gejyo F, Iwasaki Y, Fukagawa M. Kazama JJ, et al. Among authors: yamamoto s. Ther Apher Dial. 2006 Jun;10(3):262-6. doi: 10.1111/j.1744-9987.2006.00375.x. Ther Apher Dial. 2006. PMID: 16817791

4

Autophagy: a two-edged sword in diabetes mellitus.

Yamamoto S, Kazama JJ, Fukagawa M. Yamamoto S, et al. Biochem J. 2013 Dec 15;456(3):e1-3. doi: 10.1042/BJ20131282. Biochem J. 2013. PMID: 24266345

5

A hip fracture in a dialysis patient with Aβ2M amyloidosis.

Kazama JJ, Yamamoto S, Wakasugi M, Narita I. Kazama JJ, et al. Among authors: yamamoto s. Kidney Int. 2014 Jan;85(1):214-5. doi: 10.1038/ki.2013.412. Kidney Int. 2014. PMID: 24380913 Free article. No abstract available.

6

Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients.

Yamamoto S, Kido R, Onishi Y, Fukuma S, Akizawa T, Fukagawa M, Kazama JJ, Narita I, Fukuhara S. Yamamoto S, et al. PLoS One. 2015 Apr 13;10(4):e0122691. doi: 10.1371/journal.pone.0122691. eCollection 2015. PLoS One. 2015. PMID: 25874620 Free PMC article. Clinical Trial.

7

Uremic Toxicity and Bone in CKD.

Yamamoto S, Fukagawa M. Yamamoto S, et al. J Nephrol. 2017 Oct;30(5):623-627. doi: 10.1007/s40620-017-0406-x. Epub 2017 Jun 1. J Nephrol. 2017. PMID: 28573386 Review.

8

Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.

Komaba H, Wang M, Taniguchi M, Yamamoto S, Nomura T, Schaubel DE, Smith AR, Zee J, Karaboyas A, Bieber B, Fukagawa M, Tentori F. Komaba H, et al. Among authors: yamamoto s. Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1489-1497. doi: 10.2215/CJN.13091216. Epub 2017 Jul 19. Clin J Am Soc Nephrol. 2017. PMID: 28724618 Free PMC article.

9

Potential Benefit Associated With Delaying Initiation of Hemodialysis in a Japanese Cohort.

Higuchi S, Nakaya I, Yoshikawa K, Chikamatsu Y, Sada KE, Yamamoto S, Takahashi S, Sasaki H, Soma J. Higuchi S, et al. Among authors: yamamoto s. Kidney Int Rep. 2017 Feb 10;2(4):594-602. doi: 10.1016/j.ekir.2017.01.015. eCollection 2017 Jul. Kidney Int Rep. 2017. PMID: 29318218 Free PMC article.

10

Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Yamamoto S, Karaboyas A, Komaba H, Taniguchi M, Nomura T, Bieber BA, De Sequera P, Christensson A, Pisoni RL, Robinson BM, Fukagawa M. Yamamoto S, et al. BMC Nephrol. 2018 Oct 5;19(1):253. doi: 10.1186/s12882-018-1056-5. BMC Nephrol. 2018. PMID: 30290781 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10,351 results

Search Page